QOF financial modelling
QOF Income 2026/27
Indicative QOF income from published achievement, registered lists and disease registers, with each practice's history and a guide to how the money is worked out.
Indicative estimates.Not payment statements. The prevalence factor is reconstructed from published data; CQRS rebases the statutory one against a range that is not published, and payment also depends on CQRS's own data and declarations.
Practice and years
Indicator reference
Choose a practice above to estimate its income. Until then each indicator is shown for a practice of exactly national-average size (CPI 1), before prevalence adjustment: points × £227.95.
| Indicator | Description | Points | Thresholds | Prevalence adjustment | At national average |
|---|---|---|---|---|---|
| AF006Clinical | Patients with atrial fibrillation in whom stroke risk has been assessed using CHA2DS2-VASc in the preceding 12 months (excluding those with a previous score of 2 or more). Show full wording |
12 | 40-95% | adjusted by its disease register | £2,735.40 |
| BP002Public Health | Patients aged 45 or over who have a record of blood pressure in the preceding 5 years. Show full wording |
15 | 50-90% | not prevalence-adjusted (statute) | £3,419.25 |
| AF008Clinical | Patients on the AF register with CHA2DS2-VASc score of 2 or more, prescribed a DOAC or, if unsuitable/declined, a Vitamin K antagonist. Show full wording |
12 | 70-95% | adjusted by its disease register | £2,735.40 |
| SMOK002Public Health | Patients with specified long-term conditions whose notes record smoking status in the preceding 12 months. Show full wording |
25 | 50-90% | combined register not published: no factor | £5,698.75 |
| CHD005Clinical | Patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. Show full wording |
7 | 56-96% | adjusted by its disease register | £1,595.65 |
| SMOK004Public Health | Patients aged 15 or over recorded as current smokers who have a record of offer of support and treatment within the preceding 24 months. Show full wording |
12 | 40-90% | not prevalence-adjusted (statute) | £2,735.40 |
| CD001Clinical | Patients with CHD, stroke or TIA, aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). Show full wording |
41 | 40-90% | combined register not published: no factor | £9,345.95 |
| VI001Public Health | Babies reaching 8 months in the preceding 12 months who received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before age 8 months. Show full wording |
18 | 89-96% (or improvement 5-18 percentage points) | not prevalence-adjusted (statute) | £4,103.10 |
| CD002Clinical | Patients with CHD, stroke or TIA, aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). Show full wording |
20 | 46-90% | combined register not published: no factor | £4,559.00 |
| VI002Public Health | Children reaching 18 months in the preceding 12 months who received at least 1 dose of MMR or MMRV between ages 12 and 18 months. Show full wording |
18 | 86-96% (or improvement 5-23 percentage points) | not prevalence-adjusted (statute) | £4,103.10 |
| CHOL003Clinical | Patients on the CHD, PAD, Stroke/TIA or CKD register currently prescribed a statin or, if declined/unsuitable, another lipid-lowering therapy. Show full wording |
20 | 70-95% | combined register not published: no factor | £4,559.00 |
| VI003Public Health | Children reaching 5 years in the preceding 12 months who received a second dose of MMR or MMRV before age 5 years. Show full wording |
18 | 81-96% (or improvement 5-30 percentage points) | not prevalence-adjusted (statute) | £4,103.10 |
| CHOL004Clinical | Patients on the CHD, PAD or Stroke/TIA register with most recent cholesterol in the preceding 12 months at target (LDL ≤2.0 or non-HDL ≤2.6 mmol/L). Show full wording |
44 | 20-50% | combined register not published: no factor | £10,029.80 |
| VI004Public Health | Patients who reached 80 years old in the preceding 12 months who have received shingles vaccine between ages 70 and 79 years. Show full wording |
10 | 50-60% | not prevalence-adjusted (statute) | £2,279.50 |
| HF008Clinical | Patients with heart failure diagnosed on or after 1 April 2023, confirmed appropriately by echocardiogram or specialist assessment. Show full wording |
6 | 50-90% | adjusted by its disease register | £1,367.70 |
| OB004Public Health | Adults living with obesity referred to a weight management programme in the QOF year. Show full wording |
5 | 10-30% | adjusted by its disease register | £1,139.75 |
| HF007Clinical | Patients with heart failure on the register who have had a review in the preceding 12 months including functional capacity and medication review. Show full wording |
7 | 50-90% | adjusted by its disease register | £1,595.65 |
| OB005Public Health | Adults living with obesity eligible for shared decision-making and pharmacotherapy pathway support. Show full wording |
13 | 50-80% | adjusted by its disease register | £2,963.35 |
| CS005Public Health | Women/people with a cervix aged 25–49 with adequate cervical screening test in the previous 3 years and 6 months. Show full wording |
7 | 45-80% | target population factor not modelled | £1,595.65 |
| HF009Clinical | Patients with HFrEF currently treated with four-pillar therapy: ACEi/ARNI/ARB, beta blocker, MRA and SGLT2 inhibitor. Show full wording |
12 | 20-50% | sub-register not held: no factor | £2,735.40 |
| CS006Public Health | Women/people with a cervix aged 50–64 with adequate cervical screening test in the previous 5 years and 6 months. Show full wording |
4 | 45-80% | target population factor not modelled | £911.80 |
| HYP010Clinical | Patients with hypertension aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). Show full wording |
38 | 40-85% | adjusted by its disease register | £8,662.10 |
| HYP011Clinical | Patients with hypertension aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). Show full wording |
14 | 40-85% | adjusted by its disease register | £3,191.30 |
| STIA007Clinical | Patients with non-haemorrhagic stroke or history of TIA who have a record in the preceding 12 months that an anti-platelet agent or anti-coagulant is being taken. Show full wording |
4 | 57-97% | adjusted by its disease register | £911.80 |
| DM006Clinical | Patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). Show full wording |
3 | 57-97% | adjusted by its disease register | £683.85 |
| DM014Clinical | Patients newly diagnosed with diabetes who have a record of referral to a structured education programme within 9 months of entry on to the register. Show full wording |
11 | 40-90% | adjusted by its disease register | £2,507.45 |
| DM020Clinical | Patients with diabetes whose latest IFCC-HbA1c in the preceding 12 months is 58 mmol/mol or less. Show full wording |
17 | 35-75% | adjusted by its disease register | £3,875.15 |
| DM021Clinical | Patients with diabetes, on the register, with moderate or severe frailty in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. Show full wording |
10 | 52-92% | adjusted by its disease register | £2,279.50 |
| DM034Clinical | Patients with diabetes and no CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. Show full wording |
8 | 50-90% | adjusted by its disease register | £1,823.60 |
| DM035Clinical | Patients with diabetes and established CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. Show full wording |
8 | 50-90% | adjusted by its disease register | £1,823.60 |
| DM036Clinical | Patients with diabetes, on the register aged 79 years and under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). Show full wording |
27 | 38-90% | adjusted by its disease register | £6,154.65 |
| DM037Clinical | Patients with diabetes receiving all eight annual care processes in the preceding 12 months. Show full wording |
10 | 35-75% | adjusted by its disease register | £2,279.50 |
| AST007Clinical | Patients with asthma on the register who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. Show full wording |
20 | 45-70% | adjusted by its disease register | £4,559.00 |
| AST012Clinical | Patients with a new diagnosis of asthma on or after 1 April 2025 with a record of an objective test between 3 months before or 3 months after diagnosis. Show full wording |
15 | 45-80% | adjusted by its disease register | £3,419.25 |
| COPD010Clinical | Patients with COPD who have had a review in the preceding 12 months including exacerbation count and MRC breathlessness score. Show full wording |
9 | 50-90% | adjusted by its disease register | £2,051.55 |
| DEM004Clinical | Patients with dementia who have had a face-to-face or remote care plan review in the preceding 12 months. Show full wording |
14 | 35-70% | adjusted by its disease register | £3,191.30 |
| MH002Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with a comprehensive care plan documented in the preceding 12 months. Show full wording |
5 | 40-90% | adjusted by its disease register | £1,139.75 |
| MH003Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months. Show full wording |
3 | 50-90% | adjusted by its disease register | £683.85 |
| MH006Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 12 months. Show full wording |
3 | 50-90% | adjusted by its disease register | £683.85 |
| MH007Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months. Show full wording |
3 | 50-90% | adjusted by its disease register | £683.85 |
| MH011Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with lipids recorded in the preceding 12 months. Show full wording |
7 | 50-90% | adjusted by its disease register | £1,595.65 |
| MH012Clinical | Patients with schizophrenia, bipolar affective disorder and other psychoses with glucose or HbA1c recorded in the preceding 12 months. Show full wording |
7 | 50-90% | adjusted by its disease register | £1,595.65 |
| NDH003Clinical | Patients with non-diabetic hyperglycaemia or previous gestational diabetes who have had HbA1c or fasting blood glucose in the preceding 12 months. Show full wording |
20 | 50-90% | adjusted by its disease register | £4,559.00 |